Download PDF
CC BY 4.0 · Arq Neuropsiquiatr 2022; 80(12): 1254-1261
DOI: 10.1055/s-0042-1758864
Original Article

Clinicopathological and prognostic significance of COX-2 in glioma patients: a meta-analysis

Significância clinicopatológica e prognóstica da COX-2 em pacientes com glioma: uma metanálise
Jun Wang 
1   China Three Gorges University, The People's Hospital, Yichang, Hubei Province, China.
,
Chenyan Xiang 
1   China Three Gorges University, The People's Hospital, Yichang, Hubei Province, China.
,
Yi Cai 
2   China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.
3   China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
,
Ziyi Mei 
2   China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.
3   China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
,
Qianqian Lu 
2   China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.
3   China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
,
Binbin Liu 
2   China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.
3   China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
,
Lili Zou 
2   China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.
3   China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
› Author Affiliations Support The authors declare that the present study has received funding from the Hubei Office of Education Foundation (grant no. B2016022).
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background In recent years, cyclooxygenase-2 (COX-2) has been identified as a cancer stem cell (CSC) marker in gliomas. Nevertheless, the clinical and prognostic significance of COX-2 in glioma patients remains controversial.

Objective To evaluate the correlation of COX-2 with the prognosis in glioma patients.

Methods Eligible studies on this subject were included, and pooled odd ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95%CIs) were estimated. Publication bias was assessed through funnel plots, and heterogeneity and sensitivity were analyzed as well.

Results In the present study, 11 articles with a total of 641 patients were included. The high expression of COX-2 in glioma patients was negatively associated with overall survival (OS) (n = 11; HR = 2.26; 95%CI = 1.79–2.86), and the subgroup analysis showed no differences in OS between Asian (n = 5; HR = 2.16; 95%CI = 1.57–2.97) and non-Asian (n = 6; HR = 2.39; 95%CI = 1.69–3.38) glioma patients. The Begg funnel plots test indicated that there was no evident risk of publication bias in the meta-analysis.

Conclusion The present study suggests that COX-2 could be recommended as a useful pathological and prognostic biomarker in the clinical practice.

Resumo

Introdução Nos últimos anos, a ciclooxigenase-2 (COX-2) foi identificada como um marcador de células-tronco cancerígenas (CSC) em gliomas. No entanto, o significado clínico e prognóstico da COX-2 em pacientes com glioma permanece controverso.

Objetivo Avaliar a correlação da COX-2 com o prognóstico em pacientes com glioma.

Métodos Estudos elegíveis sobre este assunto foram incluídos e foram estimados odds ratios (ORs) e hazard ratios (HRs) com intervalos de confiança de 95% (IC 95%). O viés de publicação foi avaliado por meio de gráficos de funil, e a heterogeneidade e a sensibilidade também foram analisadas.

Resultados No presente estudo foram incluídos 11 artigos com um total de 641 pacientes. A alta expressão de COX-2 em pacientes com glioma foi negativamente associada à sobrevida global (OS) (n = 11; HR = 2,26; IC 95% = 1,79-2,86), e a análise de subgrupo não mostrou diferenças na OS entre asiáticos (n = 5; HR = 2,16; IC 95% = 1,57–2,97) e não asiáticos (n = 6; HR = 2,39; IC 95% = 1,69–3,38) pacientes com glioma. O teste de gráficos de funil de Begg indicou que não havia risco evidente de viés de publicação na metanálise.

Conclusão O presente estudo sugere que a COX-2 pode ser recomendada como um biomarcador patológico e prognóstico útil na prática clínica.

Keywords

Cyclooxygenase 2 - Glioma - Meta-Analysis - Survival

Palavras-chave

Ciclo-oxigenase 2 - Glioma - Metanálise - Sobrevida

Authors' Contributions

All authors have contributed to the intellectual content of the present paper and have made significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, have contributed to drafting or revising the article for intellectual content and approved the final version submitted for publication.




Publication History

Received: 20 October 2021

Accepted: 25 April 2022

Article published online:
29 December 2022

© 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Weller M, van den Bent M, Preusser M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021; 18 (03) 170-186
    CrossrefPubMedSearch in Google Scholar
  • 2 Ostrom QT, Bauchet L, Davis FG. et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-oncol 2014; 16 (07) 896-913
    CrossrefPubMedSearch in Google Scholar
  • 3 Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol 2019; 15 (07) 405-417
    CrossrefPubMedSearch in Google Scholar
  • 4 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131 (06) 803-820
    CrossrefPubMedSearch in Google Scholar
  • 5 Qi Y, Liu B, Sun Q, Xiong X, Chen Q. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. Front Immunol 2020; 11: 578877
    CrossrefPubMedSearch in Google Scholar
  • 6 Kunadis E, Lakiotaki E, Korkolopoulou P, Piperi C. Targeting post-translational histone modifying enzymes in glioblastoma. Pharmacol Ther 2021; 220: 107721
    CrossrefPubMedSearch in Google Scholar
  • 7 Chen H, Xu C, Yu Q. et al. Comprehensive landscape of STEAP family functions and prognostic prediction value in glioblastoma. J Cell Physiol 2021; 236 (04) 2988-3000
    CrossrefPubMedSearch in Google Scholar
  • 8 Kumagai T, Usami H, Matsukawa N. et al. Functional interaction between cyclooxygenase-2 and p53 in response to an endogenous electrophile. Redox Biol 2015; 4: 74-86
    CrossrefPubMedSearch in Google Scholar
  • 9 Frejborg E, Salo T, Salem A. Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis. Int J Mol Sci 2020; 21 (23) E9246
    CrossrefPubMedSearch in Google Scholar
  • 10 DuBois RN, Awad J, Morrow J, Roberts II LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 1994; 93 (02) 493-498
    CrossrefPubMedSearch in Google Scholar
  • 11 Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266 (20) 12866-12872
    CrossrefPubMedSearch in Google Scholar
  • 12 Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 1996; 10 (01) 1-17
    CrossrefPubMedSearch in Google Scholar
  • 13 Alhouayek M, Muccioli GG. COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci 2014; 35 (06) 284-292
    CrossrefPubMedSearch in Google Scholar
  • 14 López DE, Ballaz SJ. The Role of Brain Cyclooxygenase-2 (Cox-2) Beyond Neuroinflammation: Neuronal Homeostasis in Memory and Anxiety. Mol Neurobiol 2020; 57 (12) 5167-5176
    CrossrefPubMedSearch in Google Scholar
  • 15 Han JA, Kim JI, Ongusaha PP. et al. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J 2002; 21 (21) 5635-5644
    CrossrefPubMedSearch in Google Scholar
  • 16 Patel MI, Subbaramaiah K, Du B. et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005; 11 (05) 1999-2007
    CrossrefPubMedSearch in Google Scholar
  • 17 You S, Li R, Park D. et al. Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer. Mol Cancer Ther 2014; 13 (03) 606-616
    CrossrefPubMedSearch in Google Scholar
  • 18 Guo W, Zhang Z, Li G. et al. Pyruvate Kinase M2 Promotes Prostate Cancer Metastasis Through Regulating ERK1/2-COX-2 Signaling. Front Oncol 2020; 10: 544288
    CrossrefPubMedSearch in Google Scholar
  • 19 Peng Y, Wang Y, Tang N. et al. Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res 2018; 37 (01) 248-261
    CrossrefPubMedSearch in Google Scholar
  • 20 Chen Y, Chen HN, Wang K. et al. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J Hepatol 2019; 70 (01) 66-77
    CrossrefPubMedSearch in Google Scholar
  • 21 Edelman MJ, Wang X, Hodgson L. et al; Alliance for Clinical Trials in Oncology. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol 2017; 35 (19) 2184-2192
    CrossrefPubMedSearch in Google Scholar
  • 22 Nagaraju GP, El-Rayes BF. Cyclooxygenase-2 in gastrointestinal malignancies. Cancer 2019; 125 (08) 1221-1227
    CrossrefPubMedSearch in Google Scholar
  • 23 Wu L, Amarachintha S, Xu J, Oley Jr F, Du W. Mesenchymal COX2-PG secretome engages NR4A-WNT signalling axis in haematopoietic progenitors to suppress anti-leukaemia immunity. Br J Haematol 2018; 183 (03) 445-456
    CrossrefPubMedSearch in Google Scholar
  • 24 Wells G. , et al. , The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. —, 2000. —
  • 25 Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019; 22 (04) 153-160
    CrossrefPubMedSearch in Google Scholar
  • 26 Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8 (16) 1-16
    CrossrefPubMedSearch in Google Scholar
  • 27 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17 (24) 2815-2834
    CrossrefPubMedSearch in Google Scholar
  • 28 Cohen JF, Chalumeau M, Cohen R, Korevaar DA, Khoshnood B, Bossuyt PM. Cochran's Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracy. J Clin Epidemiol 2015; 68 (03) 299-306
    CrossrefPubMedSearch in Google Scholar
  • 29 Friedman HS, Colvin OM, Kaufmann SH. et al. Cyclophosphamide resistance in medulloblastoma. Cancer Res 1992; 52 (19) 5373-5378
    PubMedSearch in Google Scholar
  • 30 Castelli MG, Chiabrando C, Fanelli R. et al. Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 1989; 49 (06) 1505-1508
    PubMedSearch in Google Scholar
  • 31 Paoletti P, Chiabrando C, Gaetani P. et al. Prostaglandins in human brain tumors. J Neurosurg Sci 1989; 33 (01) 65-69
    PubMedSearch in Google Scholar
  • 32 Shao N, Feng N, Wang Y, Mi Y, Li T, Hua L. Systematic review and meta-analysis of COX-2 expression and polymorphisms in prostate cancer. Mol Biol Rep 2012; 39 (12) 10997-11004
    CrossrefPubMedSearch in Google Scholar
  • 33 Hugo HJ, Saunders C, Ramsay RG, Thompson EW. New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis. J Mammary Gland Biol Neoplasia 2015; 20 (3-4): 109-119
    CrossrefPubMedSearch in Google Scholar
  • 34 Lu SC, Zhong JH, Tan JT. et al. Association between COX-2 gene polymorphisms and risk of hepatocellular carcinoma development: a meta-analysis. BMJ Open 2015; 5 (10) e008263
    CrossrefPubMedSearch in Google Scholar
  • 35 Zhan P, Qian Q, Yu LK. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis 2013; 5 (01) 40-47
    CrossrefPubMedSearch in Google Scholar
  • 36 Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc Ser A Stat Soc 1988; 151 (03) 419-463
    CrossrefSearch in Google Scholar
  • 37 Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001; 61 (11) 4375-4381
    PubMedSearch in Google Scholar
  • 38 Castilla EA, Prayson RA, Kanner AA. et al. Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer 2003; 98 (07) 1465-1472
    CrossrefPubMedSearch in Google Scholar
  • 39 Lee M-C. et al. Cyclooxygenase-2 expression predicts prognosis in astrocytic tumors. J Korean Neurosurg Soc 2004; 36 (06) 437-442
    Search in Google Scholar
  • 40 Buccoliero AM, Caldarella A, Arganini L. et al. Cyclooxygenase-2 in oligodendroglioma: possible prognostic significance. Neuropathology 2004; 24 (03) 201-207
    CrossrefPubMedSearch in Google Scholar
  • 41 Perdiki M, Korkolopoulou P, Thymara I. et al. Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Mol Cell Biochem 2007; 295 (1-2): 75-83
    CrossrefPubMedSearch in Google Scholar
  • 42 Onguru O, Gamsizkan M, Ulutin C, Gunhan O. Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma. Neuropathology 2008; 28 (01) 29-34
    CrossrefPubMedSearch in Google Scholar
  • 43 El-Sayed M, Taha MM. Immunohistochemical expression of cycloxygenase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival. Turk Neurosurg 2011; 21 (01) 27-35
    PubMedSearch in Google Scholar
  • 44 Myung J, Cho BK, Kim YS, Park SH. Snail and Cox-2 expressions are associated with WHO tumor grade and survival rate of patients with gliomas. Neuropathology 2010; 30 (03) 224-231
    CrossrefPubMedSearch in Google Scholar
  • 45 Chen L, Wang X, Wang H. et al. miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. Eur J Cancer 2012; 48 (16) 3104-3111
    CrossrefPubMedSearch in Google Scholar
  • 46 Wang X, Chen Y, Zhang S. et al. Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis. J Neurooncol 2015; 125 (02) 277-285
    CrossrefPubMedSearch in Google Scholar
  • 47 Zhang F, Chu J, Wang F. Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas. Oncol Lett 2017; 14 (02) 1303-1308
    CrossrefPubMedSearch in Google Scholar